GS
TAK icon

GTS Securities’s Takeda Pharmaceutical TAK Stock Holding History

GTS Securities’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,481
Closed -$210K – 1819
2025
Q4 		$210K Buy
+13,481
New +$193K 0.01% 1254
2025
Q1 		– Sell
-97,558
Closed -$1.29M – 1562
2024
Q4 		$1.29M Buy
+97,558
New +$1.34M 0.06% 252
2024
Q3 		– Sell
-38,294
Closed -$496K – 4432
2024
Q2 		$496K Sell
38,294
-330,165
-90% -$4.37M ﹤0.01% 2708
2024
Q1 		$5.12M Sell
368,459
-50,461
-12% -$734K 0.01% 844
2023
Q4 		$5.98M Buy
+418,920
New +$5.94M 0.01% 885

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GTS Securities's TAK Position: Q1 2026 in Review

GTS Securities sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 13,481 shares — an estimated $210K sold.

GTS Securities first reported a position in TAK in Q4 2023 and held it in 5 quarters. The position peaked at $5.98M in Q4 2023. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • GTS Securities reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • GTS Securities sold 13,481 Takeda Pharmaceutical shares in Q1 2026, an estimated $210K.
  • GTS Securities first reported a position in Takeda Pharmaceutical in Q4 2023 and held it in 5 quarters.
  • GTS Securities's Takeda Pharmaceutical position peaked at $5.98M in Q4 2023.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.